Although this principle originates outside the CNS, it is equally applicable to CNS disorders: in depression, elevated inflammatory markers may indicate a better response to cytokine inhibitors or glial‐targeting agents such as minocycline or anti‐TNF therapies [693, 807]. The gene discussed is TNF; the disease is depressive symptom measurement.